Advanced Filters
noise

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,902 clinical trials
L Luca Bertolaccini

Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site

investigate the molecular differences between primitive lung cancer and the metastatic site.

18 years of age All Phase N/A
F Francisco Cartujano, MD

Advancing Lung Cancer Screening One Text at a Time

The purpose of this study is to assess the feasibility, acceptability, and preliminary impact of text messaging to promote lung cancer screening.

50 - 80 years of age All Phase N/A
S Slavisa Tubin, MD

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky …

18 years of age All Phase N/A
D Duc M Ha, MD MAS

Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer

Lung cancer is the second-most commonly diagnosed cancer among U.S. Veterans. Substantial advances have been made in early detection through screening and treatment. The longevity of Veterans following lung cancer diagnosis and treatment has increased. Following treatment however, many Veterans experience increased symptom burden, particularly in shortness of breath, fatigue, …

18 years of age All Phase N/A
J Judith RAIMBOURG, Dr

Clinico-biological Data Collection Study of Metastatic Lung Cancer

RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective …

18 years of age All Phase N/A
P Peter MacDowell, BA, MS

Increasing Lung Cancer Screening Uptake Among Emergency Department Patients

The objective of the proposed clinical trial is to determine if we can increase LCS among ED patients using a combination of facilitated referral to an LCS program plus text message reminders to get screened. Step 1 of the approach is to identify participants that are eligible for LCS. Step …

50 - 80 years of age All Phase N/A
W Wu yilong, phD

SKB500 Combinations in Patients With Small Cell Lung Cancer

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

18 - 75 years of age All Phase 2

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).

18 years of age All Phase 1/2
L Liang Zhao

DLL3-Targeted PET/CT in Small Cell Lung Cancer

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.

18 - 80 years of age All Phase N/A
Y Yi Hu, M.D

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation. Treatment Regimen: All enrolled subjects will receive IBI351 combined with cetuximab β injection. Treatment will continue until disease …

18 - 75 years of age All Phase 2

Simplify language using AI